Advanced search
1 file | 392.40 KB

Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome in children: results of the EWOG-MDS 98 study

(2011) LEUKEMIA. 25(3). p.455-462
Author
Organization
Abstract
We report on the outcome of children with advanced primary myelodysplastic syndrome (MDS) transplanted from an HLA-matched sibling (MSD) or an unrelated donor (UD) following a preparative regimen with busulfan, cyclophosphamide and melphalan. Ninety-seven patients with refractory anemia with excess blasts (RAEB, n = 53), RAEB in transformation (RAEB-T, n = 29) and myelodysplasia-related acute myeloid leukemia (MDR-AML, n = 15) enrolled in the European Working Group of MDS in Childhood (EWOG-MDS) 98 study and given hematopoietic stem cell transplantation (HSCT) were analyzed. Median age at HSCT was 11.1 years (range 1.4-19.0). Thirty-nine children were transplanted from an MSD, whereas 58 were given the allograft from a UD (n = 57) or alternative family donor (n = 1). Stem cell source was bone marrow (n = 69) or peripheral blood (n = 28). With a median follow-up of 3.9 years (range 0.1-10.9), the 5-year probability of overall survival is 63%, while the 5-year cumulative incidence of transplantation-related mortality (TRM) and relapse is 21% each. Age at HSCT greater than 12 years, interval between diagnosis and HSCT longer than 4 months, and occurrence of acute or extensive chronic graft-versus-host disease were associated with increased TRM. The risk of relapse increased with more advanced disease. This study indicates that HSCT following a myeloablative preparative regimen offers a high probability of survival for children with advanced MDS.
Keywords
children, stem cell transplantation, BONE-MARROW-TRANSPLANTATION, JUVENILE MYELOMONOCYTIC LEUKEMIA, ACUTE MYELOID-LEUKEMIA, myelodysplastic syndrome, CLASSIFICATION, VERSUS-HOST-DISEASE, GRAFT, CHILDHOOD, SURVIVAL, EXPERIENCE, THERAPY

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 392.40 KB

Citation

Please use this url to cite or link to this publication:

Chicago
Strahm, B, P Nollke, M Zecca, ET Korthof, M Bierings, I Furlan, P Sedlacek, et al. 2011. “Hematopoietic Stem Cell Transplantation for Advanced Myelodysplastic Syndrome in Children: Results of the EWOG-MDS 98 Study.” Leukemia 25 (3): 455–462.
APA
Strahm, B, Nollke, P., Zecca, M., Korthof, E., Bierings, M., Furlan, I., Sedlacek, P., et al. (2011). Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome in children: results of the EWOG-MDS 98 study. LEUKEMIA, 25(3), 455–462.
Vancouver
1.
Strahm B, Nollke P, Zecca M, Korthof E, Bierings M, Furlan I, et al. Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome in children: results of the EWOG-MDS 98 study. LEUKEMIA. 2011;25(3):455–62.
MLA
Strahm, B, P Nollke, M Zecca, et al. “Hematopoietic Stem Cell Transplantation for Advanced Myelodysplastic Syndrome in Children: Results of the EWOG-MDS 98 Study.” LEUKEMIA 25.3 (2011): 455–462. Print.
@article{1198868,
  abstract     = {We report on the outcome of children with advanced primary myelodysplastic syndrome (MDS) transplanted from an HLA-matched sibling (MSD) or an unrelated donor (UD) following a preparative regimen with busulfan, cyclophosphamide and melphalan. Ninety-seven patients with refractory anemia with excess blasts (RAEB, n = 53), RAEB in transformation (RAEB-T, n = 29) and myelodysplasia-related acute myeloid leukemia (MDR-AML, n = 15) enrolled in the European Working Group of MDS in Childhood (EWOG-MDS) 98 study and given hematopoietic stem cell transplantation (HSCT) were analyzed. Median age at HSCT was 11.1 years (range 1.4-19.0). Thirty-nine children were transplanted from an MSD, whereas 58 were given the allograft from a UD (n = 57) or alternative family donor (n = 1). Stem cell source was bone marrow (n = 69) or peripheral blood (n = 28). With a median follow-up of 3.9 years (range 0.1-10.9), the 5-year probability of overall survival is 63%, while the 5-year cumulative incidence of transplantation-related mortality (TRM) and relapse is 21% each. Age at HSCT greater than 12 years, interval between diagnosis and HSCT longer than 4 months, and occurrence of acute or extensive chronic graft-versus-host disease were associated with increased TRM. The risk of relapse increased with more advanced disease. This study indicates that HSCT following a myeloablative preparative regimen offers a high probability of survival for children with advanced MDS.},
  author       = {Strahm, B and Nollke, P and Zecca, M and Korthof, ET and Bierings, M and Furlan, I and Sedlacek, P and Chybicka, A and Schmugge, M and Bordon Cueto De Braem, Maria and Peters, C and O'Marcaigh, A and de Heredia, CD and Bergstraesser, E and De Moerloose, Barbara and van den Heuvel-Eibrink, MM and Stary, J and Trebo, M and Wojcik, D and Niemeyer, CM and Locatelli, F},
  issn         = {0887-6924},
  journal      = {LEUKEMIA},
  keywords     = {children,stem cell transplantation,BONE-MARROW-TRANSPLANTATION,JUVENILE MYELOMONOCYTIC LEUKEMIA,ACUTE MYELOID-LEUKEMIA,myelodysplastic syndrome,CLASSIFICATION,VERSUS-HOST-DISEASE,GRAFT,CHILDHOOD,SURVIVAL,EXPERIENCE,THERAPY},
  language     = {eng},
  number       = {3},
  pages        = {455--462},
  title        = {Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome in children: results of the EWOG-MDS 98 study},
  url          = {http://dx.doi.org/10.1038/leu.2010.297},
  volume       = {25},
  year         = {2011},
}

Altmetric
View in Altmetric
Web of Science
Times cited: